氧驱动雾化吸入重组人干扰素-α2a注射液治疗婴幼儿毛细支气管炎的疗效观察

摘要

Objective To explore the clinical effects of oxygen-driven atomized inhalation of recombinant human inter-feron-α2a injection in the treatment of infantile capillary bronchitis. Methods 240 infant patients with capillary bron-chitis were assigned to a control group and a treatment group according to their disease conditions, with 120 patients in each group. The control group received regular treatment(oxygen uptake, atomized inhalation of pulmicort respulas+nebulized terbutaline sulphate solution used for anti-inflammation and antiasthma, aspiration of sputum, antibiotics giv-en to infants suspected to be complicated with bacterial infection, intravenous drip of methylprednisolone given to in-fants with severe symptoms, etc.); The treatment group further received oxygen-driven atomized inhalation of 600,000 international units of recombinant human interferon-α2a injection, once a day for 5 days. Clinical effects and main ob-servational indices between the two groups were compared. Results Total effective rate was 95.0% in the treatment group and 78.3%in the control group, and the differences between the two groups were statistically significantly(P<0.05). Alleviating time of asthma, disappearing time of lung rale, time of persistent cough and hospitalization time in the treatment group were all lower than those in the control group, and the differences between the two groups were statisti cally significant (P<0.05). Significant adverse events were not detected during the treatment period of oxygen-driven atomized inhalation of recombinant human interferon-α2a injection applied by the infant patients. Conclusion Oxygen-driven atomized inhalation of recombinant human interferon-α 2a injection in the treatment of infantile capillary bron-chitis has an exact curative effect, and it is safe, which is worthy of clinical pediatric promotion and application.%目的：探讨氧气驱动雾化吸入重组人干扰素-α2a注射液治疗婴幼儿毛细支气管炎的临床疗效。方法将240例毛细支气管炎患儿按病情分成对照组和治疗组，各120例。对照组采用常规治疗（吸氧、雾化吸入普米克令舒+硫酸特布他林雾化液抗炎平喘，吸痰，怀疑合并细菌感染患儿给予抗菌素，严重者静脉滴注甲基强的松龙等）；治疗组在对照组治疗方案的基础上加用重组人干扰素-α2a注射液60万国际单位氧气驱动雾化吸入，每日1次，疗程5 d。对两组的临床疗效和主要观察指标进行比较。结果治疗组的总有效率95.0%，而对照组总有效率78.3%，两组差异具有统计学意义（P<0.05）。治疗组的喘息缓解时间、肺部啰音消失时间，咳嗽持续时间及住院时间均低于对照组，两组间的差异有统计学意义（P<0.05）。患儿在使用重组人干扰素-α2a注射液氧气驱动雾化吸入治疗期间均未出现明显不良反应。结论应用重组人干扰素-α2a注射液氧气驱动雾化吸入治疗小儿毛细支气管炎临床疗效确切安全，值得在儿科临床上推广和应用。